Difference between revisions of "NONHSAT076153"
| Line 1: | Line 1: | ||
| − | Please input one-sentence summary here. PCGEM1 has been characterised as a high-risk PCa marker and a potential biomarker for neoplasms responsive to chemoprevention by phytosterols <ref name="ref2" />. | + | Please input one-sentence summary here. ''PCGEM1'' (Prostate cancer gene expression marker 1) is a long non-coding RNA (lncRNA) overexpressed in prostate cancer (PCa) cells that promotes PCa initiation and progression and protects against chemotherapy-induced apoptosis <ref name="ref4" />. PCGEM1 has been characterised as a high-risk PCa marker and a potential biomarker for neoplasms responsive to chemoprevention by phytosterols <ref name="ref2" />. |
==Annotated Information== | ==Annotated Information== | ||
| Line 57: | Line 57: | ||
<ref name="ref2"> Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T & Calin GA. Long Noncoding RNA in Prostate, Bladder, and Kidney Cancer[J]. European Urology. 2014, 65(6):1140-1151. | <ref name="ref2"> Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T & Calin GA. Long Noncoding RNA in Prostate, Bladder, and Kidney Cancer[J]. European Urology. 2014, 65(6):1140-1151. | ||
</ref>(2) | </ref>(2) | ||
| − | <ref name="ref3"> Xue Y, Wang M, Kang M, et al. Association between lncrna PCGEM1 polymorphisms and prostate cancer risk[J]. Prostate cancer and prostatic diseases | + | <ref name="ref3"> Xue Y, Wang M, Kang M, et al. Association between lncrna PCGEM1 polymorphisms and prostate cancer risk[J]. Prostate cancer and prostatic diseases. 2013, 16(2):139. |
</ref>(3) | </ref>(3) | ||
| + | <ref name="ref4"> He J H, Zhang J, Han Z P, et al. Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells[J]. Journal of Experimental & Clinical Cancer Research. 2014, 33(1):72. | ||
| + | </ref>(4) | ||
</references> | </references> | ||
Revision as of 05:44, 14 November 2018
Please input one-sentence summary here. PCGEM1 (Prostate cancer gene expression marker 1) is a long non-coding RNA (lncRNA) overexpressed in prostate cancer (PCa) cells that promotes PCa initiation and progression and protects against chemotherapy-induced apoptosis [1]. PCGEM1 has been characterised as a high-risk PCa marker and a potential biomarker for neoplasms responsive to chemoprevention by phytosterols [2].
Contents
Annotated Information
Name
PCGEM1: Prostate-specific transcript, LINC00071 (HGNC)
Characteristics
PCGEM1 is located at human chromosome 2q32.3 (HGNC), consists of three exons that comprehends 1603 bp (GenBank).
Function
Over-expression leads to inhibition of apoptosis induced by doxorubicin [3]. t PRNCR1 and PCGEM1 successively interact with the androgen receptor (AR) bound at DNA-enhancer regions in a ligand-dependent fashion and facilitate the chromosomal looping between AR-bound enhancers and the promoter sequences of androgen-responsive genes [2].
Disease
prostate cancer
Expression
PCGEM1, was expressed exclusively in human prostate tissue, was dramatically upregulated in PCa tissues compared with normal prostate tissues. Prostate tissue-specific and prostate cancer-associated (Srikantan 2000). Cholesterols upregulate the expression of PCGEM1 even in androgen-insensitive prostate cancer cell lines while phytosterols reverse this effect (Ifere 2009). PCGEM1 overexpression in LNCaP and in NIH3T3 cells promotes cell proliferation and a dramatic increase in colony formation, suggesting a biological role of PCGEM1 in cell growth regulation (Petrovics 2004). Low specificity as a biomarker for prostate cancer (14%) (Bialkowska-Hobrzanska 2006).
Conservation
Please input conservation information here.
Misc
GWAS association with schizophrenia. PCGEM1 polymorphisms may contribute to PCa risk in Chinese men (Xue 2013)
Transcriptomic Nomeclature
Please input transcriptomic nomeclature information here.
Regulation
Please input regulation information here.
Allelic Information and Variation
PCGEM1 polymorphisms may contribute to PCa risk in Chinese men. Men carrying single nucleotide polymorphisms (SNPs) of PCGEM1, i.e. rs6434568 AC and rs16834898 AC, had a lower PCa risk in comparison to the ones harboring CC and AA genotypes, respectively [4].
Evolution
Please input evolution information here.
You can also add sub-section(s) at will.
Labs working on this lncRNA
- Howard Hughes Medical Institute, Department of Medicine, University of California San Diego, La Jolla, California 92093, USA.
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
- Department of Urology, School of Medicine, University of California Davis, Sacramento, California 95817, USA.
- Graduate Program, Kellogg School of Science and Technology, The Scripps Research Institute, La Jolla, California 92037, USA.
- Bioinformatics and System Biology Program, Department of Bioengineering, University of California San Diego, La Jolla, California 92093, USA.
- Neurosciences Graduate Program, Department of Biological Sciences, University of California San Diego, La Jolla, California 92093, USA.
- State Key Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, Nanjing, China.[4]
- Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China.[4]
- Department of Genetic Toxicology, Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.[4]
- Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.[4]
- Department of Environmental Genomics, School of Public Health, Nanjing Medical University, 818 East Tianyuan Road, Nanjing, Jiangsu 211166, China. [4]
References
- ↑ He J H, Zhang J, Han Z P, et al. Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells[J]. Journal of Experimental & Clinical Cancer Research. 2014, 33(1):72.
- ↑ 2.0 2.1 Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T & Calin GA. Long Noncoding RNA in Prostate, Bladder, and Kidney Cancer[J]. European Urology. 2014, 65(6):1140-1151.
- ↑ Fu X, Ravindranath L, Tran N, Petrovics G & Srivastava S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1[J]. DNA and cell biology. 2006, 25(3):135-141.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Xue Y, Wang M, Kang M, et al. Association between lncrna PCGEM1 polymorphisms and prostate cancer risk[J]. Prostate cancer and prostatic diseases. 2013, 16(2):139.
Basic Information
| Transcript ID |
NONHSAT076153 |
| Source |
NONCODE4.0 |
| Same with |
, |
| Classification |
intergenic |
| Length |
1603 nt |
| Genomic location |
chr2+:193614571..193641625 |
| Exon number |
3 |
| Exons |
193614571..193614754,193615515..193615598,193640304..193641625 |
| Genome context |
|
| Sequence |
>gi |
